PMID- 19250675
OWN - NLM
STAT- MEDLINE
DCOM- 20091123
LR  - 20090923
IS  - 1873-5835 (Electronic)
IS  - 0145-2126 (Linking)
VI  - 33
IP  - 12
DP  - 2009 Dec
TI  - Clinical features and outcome of Chinese patients with monoclonal B-cell 
      lymphocytosis.
PG  - 1619-22
LID - 10.1016/j.leukres.2009.01.029 [doi]
AB  - B-cell chronic lymphocytic leukemia (CLL) is the most common type of adult 
      leukemias in the Western countries, however, infrequent in the Eastern. A 
      diagnosis of CLL requires a count of B-lymphocytes >/=5.0x10(9)/L. Asymptomatic 
      person with <5.0x10(9)/L B-lymphocytes is defined as monoclonal B-cell 
      lymphocytosis (MBL). To compare the clinical characteristics, prognostic factors, 
      and outcome of Chinese patients with MBL and CLL, we present a study from our 
      single centre of 20 patients with MBL and 136 patients with CLL. The factors 
      included: age at diagnosis, gender, direct antiglobulin test (DAT), 
      immunoglobulin heavy chain variable gene (IgHV) mutational status, ZAP-70 
      protein, CD38 expression level, and molecular cytogenetic aberrations were 
      analyzed in MBL and CLL subgroups. The Kaplan-Meier method was used to construct 
      survival curves, and results were compared using the log-rank test. Patients in 
      the MBL category were slightly older than in the CLL category. There was no 
      significant difference of these clinical and biological characteristics between 
      patients in MBL subgroup and early stage CLL (Binet A). The incidence of positive 
      DAT was significantly increased in CLL patients at Binet B and C, compared with 
      MBL (P=0.036). IgHV gene mutation in MBL is skewed, with more than 92.3% of 
      subjects harbored mutated IgVH genes (P=0.025). The proportion of MBL patients 
      with a 13q14 deletion or trisomy 12 was similar to that of CLL patients. 
      Moreover, markers associated with poor prognosis (deletion of 11q22 or 17p13) in 
      these MBL populations were less than those in Binet B and C CLL patients 
      (P=0.025). No statistically significant differences in ZAP-70 and CD38 status 
      were observed between the MBL and CLL subgroups. During a median follow-up period 
      of 45.5 months, MBL patients had a low probability of progression, with no 
      patients transformed to aggressive non-Hodgkin's lymphoma or dying of CLL-related 
      causes. The overall survival of MBL was very similar to Binet A CLL, but longer 
      than that of CLL patients at advanced stages (Binet B and C) (P=0.024). Our study 
      demonstrated that a more indolent clinical course and superior clinical outcome 
      for patients with MBL compared to CLL.
FAU - Xu, Wei
AU  - Xu W
AD  - Department of Hematology, The First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, 300 Guangzhou Rd, Nanjing 210029, China.
FAU - Li, Jian-Yong
AU  - Li JY
FAU - Wu, Yu-Jie
AU  - Wu YJ
FAU - Cao, Xin
AU  - Cao X
FAU - Fan, Lei
AU  - Fan L
FAU - Qiao, Chun
AU  - Qiao C
FAU - Liu, Qiong
AU  - Liu Q
FAU - Yao, Lin
AU  - Yao L
FAU - Miao, Kou-Rong
AU  - Miao KR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090227
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
SB  - IM
MH  - China
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Immunophenotyping
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/immunology/*physiopathology
MH  - Lymphocytosis/immunology/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
EDAT- 2009/03/03 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/03/03 09:00
PHST- 2009/01/13 00:00 [received]
PHST- 2009/01/13 00:00 [revised]
PHST- 2009/01/26 00:00 [accepted]
PHST- 2009/03/03 09:00 [entrez]
PHST- 2009/03/03 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - S0145-2126(09)00038-1 [pii]
AID - 10.1016/j.leukres.2009.01.029 [doi]
PST - ppublish
SO  - Leuk Res. 2009 Dec;33(12):1619-22. doi: 10.1016/j.leukres.2009.01.029. Epub 2009 
      Feb 27.